The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | The CLL2-BAG trial: can CLL patients safely cease treatment after remission?
Paula Cramer, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the CLL2-BAG trial, a Phase II study evaluating the effectiveness of a sequential treatment involving the administration of bendamustine, followed by a combination of the Bcl2 antagonist, venetoclax, and the anti-CD20 antibody, obinutuzumab, in treating patients with chronic lymphocytic leukemia (CLL). Here, she states that half of the patients in the trial have ceased further treatment due to achieving complete remission and MRD negativity. She hopes that continuous follow-up will show further increasing MRD negativity, which would suggest that treatment can be stopped in the case of complete remission. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
